- Home
- INMB vs ATYR Comparison
INMB vs ATYR Comparison
Compare INMB & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INMB | ATYR |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | N/A | 59 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.3M | 83.3M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | INMB | ATYR |
|---|---|---|
| Price | $1.17 | $0.80 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 8 |
| Target Price | ★ $5.87 | $4.20 |
| AVG Volume (30 Days) | 474.3K | ★ 1.2M |
| Earning Date | 05-07-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,000.00 | N/A |
| Revenue This Year | $264.29 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.16 | $0.64 |
| 52 Week High | $11.64 | $7.29 |
Technical Indicators
Market Signals| Indicator | INMB | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 34.65 | 41.25 |
| Support Level | N/A | $0.67 |
| Resistance Level | $1.48 | $0.85 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 1.67 | 5.33 |
Price Performance
Historical ComparisonAbout INMB INmune Bio Inc.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
About ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).